Who
Miriam Kidron
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Oramed Pharmaceuticals; Director, Lifeward.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Aug 2007
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —208,125 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —209,291 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —104,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —104,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —69,999 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —72,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —69,999 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —72,000 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —208,125 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —209,291 | filing |
| 30 Mar 2026filed 31 Mar 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M435,084 at $3.31 | filing |
| 30 Mar 2026filed 31 Mar 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M435,084 at $3.31 | filing |
| 25 Mar 2026filed 27 Mar 2026 | LFWD LifewardMedical Devices | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | LFWD LifewardMedical Devices | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
News
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)ORMP · tickerreport.com · 11 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)ORMP · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Miriam Kidron; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.